transplantation

2:09
Management & resarch for CTCL at the City of Hope
Steven Rosen
1:41
Applying the right therapies to the right AML patient population
Christoph Röllig
1:28
The role of Cure Leukemia in improving access to clinical trials for patients
Charles Craddock
T-cell lymphoma: autologous or allogeneic transplant?
Francine Foss
2:27
What are the challenges of integrating therapy around autologous transplantation?
John Kuruvilla
1:03
What is induction therapy for autologous stem cell transplanation?
Michele Cavo
4:59
Conflicting results of the EMN02 and staMINA trials
Michele Cavo
2:50
Current standard of care for patients who are eligible for autologous stem cell transplantation
Michele Cavo
1:57
Promising new combinations in the treatment of myeloma
Evangelos Terpos
1:48
Managing problems in treating CLL
Anna Schuh
1:18
Treatment options for leukemia patients who fail the standard of care
Paolo Ghia
1:13
Have novel drugs made stem cell transplantation obsolete?
David Maloney
3:51
Celebrating 60 years of successful allogeneic transplant at EHA 2017
Mohamad Mohty
5:22
Lymphoid Highlights from BSH 2017
George Follows
2:27
Indications for the use of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma
Anna Sureda
3:31
Advances in multiple myeloma treatment over the last years
Vincent Rajkumar
The content of VJHemOnc is intended for healthcare professionals